MedTrace Logo

A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia

NCT02476708 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-01-23

No results posted yet for this study

Summary

This is an 8-week randomized, double-blind, placebo-controlled, parallel, fixed-dose pilot clinical trial of curcumin for the treatment of cognitive impairment in schizophrenia.The primary aim of this pilot trial is to provide an effect size estimate for the efficacy of curcumin in improving cognitive functioning in schizophrenia. Secondary goals are to determine the effect of curcumin over time on negative and positive symptoms, in association with inflammatory markers.

Conditions

Interventions

DIETARY_SUPPLEMENT

curcumin 1800mg

Curcumin, derived from turmeric root, is an over-the-counter supplement which is tolerated well.

DIETARY_SUPPLEMENT

Placebo

oral placebo capsule

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Cenk Tek, MD · Yale Unversity School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-11
Primary Completion
2017-08-24
Completion
2017-08-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02476708 on ClinicalTrials.gov